Cancer-Related Impairments and Functional Limitations Among Long-Term Cancer Survivors: Gaps and Opportunities for Clinical Practice

Larissa Nekhlyudov, MD, MPH 1; Grace B. Campbell, PhD, MSW, BSN 2,3; Kathryn H. Schmitz, PhD, MPH 4; Gabriel A. Brooks, MD, MPH 5; Anita J. Kumar, MD, MSCE 6; Patricia A. Ganz, MD 7,8,9; and Diane Von Ah, PhD, RN 10

INTRODUCTION
In 2021, an estimated 1.9 million new cases of cancer were diagnosed in the United States, and approximately 608,000 patients with cancer died of the disease.1 Today, there are approximately 17 million cancer survivors (defined as anyone with a history of cancer from the time of diagnosis until death), a number that is expected to continue increasing over the next several decades.2 This trend reflects improvements in cancer detection and treatment. However, despite the advances being made in increasing the number of survivors, many experience substantial physical and psychosocial late and long-term effects related to cancer and/or its treatment. Numerous studies have described the diverse functional limitations that affect survivors’ ability to work both during treatment and after treatment has been completed.3,4 Although many survivors do not experience work-related consequences of cancer, working-age survivors have reported changes in their employment status as a result of their diagnosis, including taking extended leave from work (paid/unpaid), changing their work schedule, changing to a less demanding job, and moving from full-time to part-time employment.5,6 Functional limitations have detrimental employment effects on individuals and their families and lead to a substantial economic burden and loss of productivity.7 In the United States, cancer-related impairments and resultant functional limitations that negatively affect work ability may lead survivors to apply for Social Security Administration (SSA) disability financial assistance. A recent consensus study report from the National Academies of Science, Engineering, and Medicine entitled Diagnosing and Treating Adult Cancers and Associated Impairments,8 requested by the SSA, provides an overview of the current status of the diagnosis, treatment, and prognosis of adult-onset cancers and the relative levels of functional limitations associated with these cancers and treatments. In this commentary, we aim to raise awareness in the clinical workforce by offering a concise overview of the epidemiology of cancer survivorship and work, common impairments and functional limitations faced by cancer survivors, and available evidence-based interventions for improving function. We describe the US SSA disability claims process, its eligibility requirements, and barriers for long-term survivors in securing approval for disability claims and offer insights for practicing clinicians in addressing and managing cancer-related impairments and functional limitations in practice.

EPIDEMIOLOGY OF CANCER SURVIVORSHIP AND WORK
Cancer survival rates are improving, and the number of survivors is expected to grow. Although many cancer types are associated with older age, an estimated 40% to 50% of cancer diagnoses worldwide occur in people 65 years old or younger, who are potentially part of the labor force.9 Work is an important indicator of health for cancer survivors,10 and returning to work is often seen as an indicator of full recovery.11 In addition to providing economic benefits, employment has been shown to positively impact physical and mental health.12,13 Despite this, a significant portion of long-term survivors experience work limitations, with many reporting reduced work ability, job loss, work disability, and unemployment.14-16 The physical and psychological impacts of cancer and/or its treatment, as well as the associated costs of care, may contribute to work limitations and disability claims.17-19 Cancer survivors may experience impairments that limit their ability to work, including physical limitations (e.g., fatigue, pain, weakness), functional limitations (e.g., mobility, memory, cognitive function), and psychosocial limitations (e.g., depression, anxiety, social isolation). These limitations can lead to decreased work productivity, increased absenteeism, and reduced job retention.20-22 Cancer survivors may also face challenges in the workplace, such as employer discrimination and lack of workplace accommodations, which can further impact their ability to work.23-25 The potential for workplace accommodations and support is a critical area for clinicians to address, as it can play a significant role in improving work outcomes for cancer survivors.26,27 This commentary aims to provide an overview of the epidemiology of cancer survivorship and work, common impairments and functional limitations faced by cancer survivors, and available evidence-based interventions for improving function. We hope to raise awareness in the clinical workforce about the potential for improving work outcomes for cancer survivors through evidence-based interventions and workplace accommodations.
and financial stability, work has been associated with emotional well-being and enhanced quality of life in cancer survivors. In the United States, the proportion returning to work is quite high in comparison with other countries, with up to 93% of cancer survivors returning to work within 12 months of their diagnosis. However, working cancer survivors often exhibit increased absenteeism, poorer work ability, and less productivity in comparison with workers without a history of cancer. In a cohort of cancer survivors, de Moor and colleagues found that employment changes were made by 41.3% of cancer survivors; 75.4% of those survivors took extended paid time off, and 46.1% made other changes, including switching to part-time work or to a less demanding job. Younger survivors, female survivors, non-White or multiracial/ethnic survivors, and those survivors with less than 20 years since their last cancer treatment were more likely to make employment changes. Moreover, cancer survivors are at greater risk for job loss than the general population and often face ongoing symptoms and functional limitations that prevent full employment.

The loss or reduction of employment not only financially harms the individual cancer survivor; this loss of productivity also has societal implications. Although there have been protections put in place to support cancer survivors (eg, the Americans with Disabilities Act and the Family and Medical Leave Act), small businesses are exempt from these laws. Furthermore, these protections fail to address the increasing number of individuals who work in some form of independent or freelance position.

Researchers have found that the financial toxicity associated with cancer and cancer treatment can be devastating, leaving survivors in financial ruin and contributing to the overwhelming health care debt in the United States.

### CANCER-RELATED IMPAIRMENTS AND FUNCTIONAL LIMITATIONS

Cancer survivors are at risk for impairments that arise from the cancer itself or as a consequence of cancer treatments, such as surgery, chemotherapy, and radiation therapy, and/or the interaction of these factors with comorbid medical conditions. Functional limitations related to cancer treatment may arise shortly after treatment initiation (acute toxicities); some acute toxicities resolve at treatment completion, but others may last for years (long-term effects). Additionally, some functional limitations may first arise months or years after treatment is completed (late effects). Regardless of onset, functional limitations may affect 1 or more organ systems, including musculoskeletal, cardiovascular, pulmonary, and psychological systems, and may include additional symptoms such as pain, fatigue, peripheral neuropathy, and sleep disturbances (Table 1).

Cancer-related impairments can lead to functional limitations, which can in turn result in changes in a person’s ability to fulfill his or her work role. The assessment of functional status among cancer survivors is, therefore, critical so that limitations can be identified and treatments can be appropriately targeted to restore and/or maximize function. Functional status assessments may be performed in the clinical setting, which may include

### TABLE 1. Functional Impairments, Their Causes, and When They Might Occur

| Impairment                      | Disease Process | Cancer Treatment | Acute | Long-Term | Late-Onset |
|---------------------------------|----------------|------------------|-------|-----------|------------|
| Pain                            | ●              | ●                | ●     | ●         | ●          |
| Cancer-related fatigue          | ●              | ●                | ●     | ●         | ●          |
| Chemotherapy-induced peripheral neuropathy | ●            | ●                | ●     | ●         | ●          |
| Lymphedema                      | ●              | ●                | ●     | ●         | ●          |
| Cachexia                        | ●              | ●                | ●     | ●         | ●          |
| Cardiotoxicity                  | ●              | ●                | ●     | ●         | ●          |
| Cognitive impairments           | ●              | ●                | ●     | ●         | ●          |
| Depression and anxiety          | ●              | ●                | ●     | ●         | ●          |
| Gastrointestinal impairments    | ●              | ●                | ●     | ●         | ●          |
| Graft-vs-host disease           | ●              | ●                | ●     | ●         | ●          |
| Musculoskeletal impairments     | ●              | ●                | ●     | ●         | ●          |
| Pulmonary toxicity              | ●              | ●                | ●     | ●         | ●          |
| Sleep disturbances              | ●              | ●                | ●     | ●         | ●          |

Other sensory impairments have not been included in the table because they are so diverse. Reproduced with permission from the National Academy of Sciences, Courtesy of the National Academies Press, Washington, DC.

*Acute refers to impairments that may occur during or immediately after treatment; long-term refers to impairments that may begin during or immediately after treatment but persist for an extended period of time; and late-onset impairments are those that may occur months or years after treatment is complete.
primary care and/or oncology practices, through the history and physical examination and through the administration of selected validated assessment tools that identify specific impairments. Screening for potential treatment-related symptoms and conditions requires asking specific questions (guided by treatment exposures), which are followed by more specific inquiry. Functional status measurements, including patient-reported outcomes and objective performance measures based on normed parameters, can assist in understanding and identifying impairments and functional limitations that place cancer survivors at risk for disability. For example, screening for peripheral neuropathy would include asking cancer survivors at risk for this condition about the presence and severity of burning pain or numbness and tingling, gait changes, and related limitations that may affect activities of daily living (eg, dressing and eating) and administer- ing a brief bedside sensory test using graduated monofilaments to objectively measure nerve sensation.19 If the neuropathy screening is positive, a referral to an appropriate specialist such as a neurologist or physiatrist is indicated for the management of the mobility impairments that can result from neuropathy. Because of the varied onset and duration of acute toxicities, long-term effects, and late effects noted previously, health care providers caring for cancer survivors, including primary care providers, oncologists, and other specialists, should regularly screen for changes in functional capacity. Screenings and more detailed assessments for selected, commonly reported cancer- and treatment-related impairments are shown in Table 2.

INTERVENING IN CANCER-RELATED IMPAIRMENTS AND FUNCTIONAL LIMITATIONS

Once they are identified, the management of cancer-related functional limitations is critical. Management strategies may include pharmacological and nonpharmacological interventions. Understanding the prevalence, etiology, and risk factors and then performing targeted screenings and assessments provide the best opportunity for intervening to attenuate or reverse these effects. Interventions that support employment productivity, including continuing to work, avoiding reduced hours, and/or returning to work, are crucial to mitigating the impact of acute, long-term, and late effects on functional status and well-being. In addition to effects that cause direct acute, late, and long-term effects, cancer survivors often incur a cluster of co-occurring symptoms that may be cancer-related or due to other chronic medical conditions, such as fatigue, sleep disturbance, and depression.40 Emotional symptom clusters may aggravate one another and often interact to exacerbate functional limitations from co-occurring impairments.41 The proper identification and treatment of one symptom in a cluster (eg, pain, anxiety, or depression) may help to resolve others and promote functional well-being. Pharmacological and nonpharmacological interventions and treatments focus on eliminating the etiology of a specific symptom or side effect. Nonpharmacological interventions may also focus on the underlying etiology while also providing education, information, and support to mitigate a symptom’s impact. Evidence for specific nonpharmacological interventions may vary. Examples of effective multimodal interventions that can be used to address functional limitations in those affected by cancer include rehabilitation services, physical therapy, exercise, and psychological interventions. Furthermore, vocational retraining may be useful to help unemployed survivors to attain gainful employment through counseling, job search assistance, and placement programs.42 Such services may be accessed through state-based programs.

Despite evidence for effectiveness, these interventions are often not provided to patients who would benefit from them. Examples of barriers to implementing these interventions include a lack of clinician knowledge about the benefits and availability, a lack of reimbursement for these programs, and a cancer care system that seldom includes professionals specializing in addressing functional limitations (eg, rehabilitation providers or exercise specialists).43 Overall, cancer survivors are at greater risk for disability due to barriers to the implementation of evidence-based interventions (ie, no systemic assessment of need or referral for established effective services) or the paucity of well-researched interventions for many impairments.

US SSA DISABILITY PROCESS

Functional limitations due to cancer, its treatment, and concomitant chronic medical conditions may not be amenable or responsive to interventions. In these situations, cancer survivors may be unable to return to work and thus may apply for disability benefits. Disability benefits in the United States are provided by the SSA through 2 programs: Social Security Disability Insurance, which provides monthly disability payments to eligible adults (less than the full retirement age) who have paid sufficient taxes through their employment, and Supplemental Security Income, which
### TABLE 2. Functional Impairments, Screenings, and Assessments

| Symptom or Impairment                                      | Recommended Screening and Assessment Instruments | Appropriate Settings and Professionals |
|-----------------------------------------------------------|--------------------------------------------------|----------------------------------------|
| Pain                                                      | (S/A) 0-10 numeric pain scale (0 = no pain; 10 = worst pain imaginable)20 | (S/A) Oncology, primary care           |
| Cancer-related fatigue                                    | (S/A) 0-10 numeric fatigue scale (0 = no fatigue; 10 = worst fatigue imaginable)21 | (S/A) Oncology, primary care           |
| Chemotherapy-induced peripheral neuropathy                | (S) PRO-CTCAE22 (A) Quantitative sensory testing to include thermal detection, pain, mechanical threshold, vibration detection thresholds23 | (S) Oncology, primary care (A) Trained neurodiagnostic technician, neurologist |
| Lymphedema                                                | (S/A) Circumferential measurements of affected and unaffected limbs24 | (S/A) Oncology, primary care (S) Oncology, primary care, lymphedema-trained physical therapist |
| Cancer                                                    | (S/A) Weight loss > 5% or BMI < 20 kg/m² with weight loss > 2% or sarcopenia with weight loss > 2%25 | (S/A) Oncology, primary care           |
| Cardiotoxicity                                            | (S) Clinical history, including treatment exposure(s), physical examination26 | (S) Oncology, primary care (A) Cardiologist, exercise physiologist, rehabilitation specialist |
| Cognitive impairment                                      | (S) FACT–Cognitive Function, MoCA28 (A) Objective neuropsychological testing, especially for executive function and psychomotor processing speed domains29 | (S) Oncology, primary care (A) Neuropsychologist |
| Depression and anxiety                                    | (S) PHQ-9, GAD-720 (A) Comprehensive psychosocial assessment20 | (S) Oncology, primary care (A) Behavioral health specialist (eg, psychologist, psychiatrist, therapist) |
| Gastrointestinal impairments                              | (S) Clinical history, including treatment exposure(s), physical examination | (S) Oncology, primary care (A) Primary care, gastroenterologist, trained pelvic floor physical therapist |
| Chronic graft-vs-host disease                             | (S/A) cGVHD Symptom Scale25 | (S) Oncology or primary * (A) Oncology, primary care, disease-based specialists (eg, pulmonologist, gastroenterologist, dermatologist) |
| Musculoskeletal impairments                               | (S) Osteoporosis: history, risk factors, and treatment exposures21 (S) Arthralgias: patient report of joint pain (eg, wrist, knees)23 (S) Muscular issues: the most common clinical measurements are range of motion, strength, and a visual analogue scale for pain (0-10, with 10 being the worst pain possible)8 (A) Osteoporosis: diagnosed through DEXA of hip and lumbar spine or quantitative ultrasonography of calcaneus33,35 | (S) Oncology or primary care (A) Oncology, primary care, endocrinologist, physical therapist, physiatrist |
| Pulmonary toxicities                                       | (S) Symptoms (cough, dyspnea, fatigue); decreased oxygen saturation36 (A) Pulmonary function tests, computed tomography imaging, bronchoscopy, thoracentesis, or lung biopsy37 | (S) Oncology or primary care (A) Pulmonologist |
| Sleep disturbances                                        | (S) PROMIS Sleep Disturbance and Sleep-Related Impairments item banks38 (A) Detailed sleep history, 2-wk sleep log; psychosocial and medication history. Some sleep disorders may also require an objective evaluation using actigraphy or polysomnography39 | (S) Oncology or primary care (A) Sleep specialists (eg, pulmonologist, psychiatrist, neurologist) |

Abbreviations: A, assessment; BMI, body mass index; cGHVD, chronic graft-vs-host disease; DEXA, dual-energy x-ray absorptiometry; FACT, Functional Assessment of Cancer Therapy; GAD-7, Generalized Anxiety Disorder-7 item scale; GI, gastrointestinal; MoCA, Montreal Cognitive Assessment; PHQ-9, Patient Health Questionnaire-9 item scale; PRO-CTCAE, Patient-Reported Outcome–Common Toxicity Criteria for Adverse Events; PROMIS, Patient-Reported Outcomes Measurement Information System; S, screening.

*Reference citations for the tools are included.

*Not useful for detecting head, neck, or torso lymphedema.
pays benefits on the basis of financial need. Those eligible for Social Security Disability Insurance may also be eligible for Medicare health insurance coverage after a 2-year waiting period, whereas those eligible for Supplemental Security Income may be eligible for Medicaid health insurance.

The SSA has a 5-step disability determination process (Table 3), which considers listings of medical impairments ("listings"), including malignant neoplastic disease (cancer), that are deemed severe enough to interfere with a person's ability to engage in gainful employment or to result in death. SSA's current listings of impairments for adult cancers (Table 3) focus predominantly on the acute treatment phases of cancer and/or the presence of metastatic cancer and, for the most part, do not include allowances for long-term impairments and functional limitations that may result from cancer treatments. If other conditions are present, individuals are referred to a condition-specific listing of impairments in other body systems. A notable exception is the listing for lymphedema, which is noted for breast cancer but not for other cancers with which lymphedema may occur, such as head and neck cancer, gynecological cancer, or melanoma. Disability allowance listings for recipients of stem cell transplants also recognize long-term effects such as graft-vs-host disease, immuno-suppressant therapy, frequent infections, and significant deterioration of other organ systems. Other late-onset impairments that were not present at the time of the cancer diagnosis are often not taken into consideration.

Between 2015 and 2019, the total disability claims awarded by the SSA for any disability decreased from 2,220,153 to 1,849,027 (a 17% decrease overall). During this time, the number of awards for which cancer was given as the primary impairment also decreased from 125,904 to 114,187 (a 9% decrease overall); claims for a primary diagnosis of cancer made up approximately 6% of all disability claims in 2019.8 The most common cancer-based disability claims were for breast, lung, colorectal, head and neck, pancreatic, nervous system, blood and bone marrow (ie, leukemia and lymphoma), liver/biliary tract, and ovarian cancers.8 The highest numbers of claims received were for lung, breast, and colorectal cancers, with the largest percentages of denials reported for breast cancer and lymphoma (with denial rates for both cancers being greater than 50%). The majority of these denials occurred because the SSA found that the claimant’s impairment or combination of impairments was not severe enough to limit his or her ability to perform any basic work activities, had not lasted or was unlikely to last at least 12 months, or was not expected to result in death; these denials occurred at step 2 of the disability determination process.8

**TABLE 3. Social Security Administration Disability Determination Process**

| Step | Question/Condition | Examples |
|------|--------------------|----------|
| 1    | Are you working (with predefined maximum earnings)? | All cancers except certain cancers associated with human immunodeficiency virus infection (which are also evaluated under immune system disorders) |
| 2    | If you are not working, is your condition severe, restricting your ability to do basic work-related activities, such as lifting, standing, walking, sitting, or remembering—for at least 12 months? | Hodgkin lymphoma treated with multi-agent chemotherapy and radiation therapy. He began to experience late effects decades after treatment. |
| 3    | Is your condition found in the list of disabling conditions? | Immune system disorders |
| 4    | Can you do the work you did previously? | Renal failure, diabetes, stroke |
| 5    | Can you do any other type of work? | Cardiac arrest, stroke, MI |

Cancer-related impairment listing
- All cancers except certain cancers associated with human immunodeficiency virus infection (which are also evaluated under immune system disorders).
- Consideration is given to complications or adverse effects of therapy, such as persistent weakness, neurological complications, cardiovascular complications, and reactive mental disorders.
- The residual effects of treatment are temporary in most instances; however, on occasion, the effects may be disabling for a consecutive period of at least 12 months. Impairment may be deemed disabling beyond 12 months when medical and other evidence justifies it.
- When the impairment or impairments have been in complete remission for at least 3 years, that is, the original tumor or a recurrence (or relapse) and any metastases have not been evident for at least 3 years, the impairment or impairments will no longer meet or medically equal the criteria of a listing in this body system.

The sources for this table include [https://www.ssa.gov/disability/professionals/bluebook/13.00-NeoplasticDiseases-Malignant-Adult.htm](https://www.ssa.gov/disability/professionals/bluebook/13.00-NeoplasticDiseases-Malignant-Adult.htm) and [https://www.ssa.gov/disability/determination.htm](https://www.ssa.gov/disability/determination.htm).
TABLE 4. Patient Scenario

Mr. C is a 56-year-old male with a history of Hodgkin lymphoma that was treated 40 years ago with splenectomy and mantle radiation. His posttreatment course has been complicated by late-onset, radiation-induced thyroid cancer status post thyroidectomy, restrictive lung disease, coronary artery disease, and aortic stenosis (status post a coronary artery bypass graft with aortic valve replacement in the past 10 years). Additionally, he has moderately well-controlled hypertension, hyperlipidemia, type 2 diabetes, and gout. His most recent cardiac testing showed preserved heart function and a normal stress test. However, he reports worsening functional limitations and trouble in performing his job duties. He works in the financial industry and is mainly sedentary at work. Specifically, he reports that his diuretic medication restricts his abilities at work. If he takes his medicine at work, he is frequently interrupted with trips to the bathroom. If he takes it at bedtime, he requires frequent bathroom trips that interrupt his sleep and dampen his ability to perform at his job. He also suffers from severe neck stiffness and drop neck syndrome related to prior radiation and finds it challenging to keep his head up during the day, particularly when he is using the computer. All of these issues adversely affect his mood, although he has not been diagnosed with depression and is not on medications. He applied for disability but failed to meet requirements.

Operate in different facilities, among other factors. In summary, as exemplified in the case scenario, Mr. C was denied disability benefits. With the current process, it is often difficult for cancer survivors to substantiate that the level of impairment or combination of impairments is severe enough to limit their ability to perform work activities. Mr. C has multiple morbidities, across several listings of disabling conditions, affecting his function; these co-occurring in themselves may not be sufficient to claim disability, but they are likely additive and progressive, and all are occurring decades after his cancer treatment. A lack of sufficient supporting medical record documentation likely contributed to the inability to substantiate the level of functional limitations and attribute them to an active disease process.

CLINICIAN ROLE IN PATIENT-CENTERED APPROACH TO ADDRESSING FUNCTIONAL IMPAIRMENTS

The clinician plays a critical role in supporting patients with cancer-related impairments and functional limitations. First, all clinicians, including primary care providers, oncologists, and other medical and allied health care professionals, have an important role in assessing patients for late and long-term effects and resultant functional limitations. Furthermore, the ability to work should be assessed regularly in all cancer survivors to detect emerging difficulties that may portend the need for an evaluation of the impairments and potentially a disability assessment. Validated tools for the determination of SSA disability may be used in clinical practice. Documentation in the electronic health record of the assessment and reassessment is critical; the use of standard patient-reported outcomes that are embedded in the electronic health record facilitates documentation and longitudinal monitoring. Once an impairment is identified, appropriate specialist referrals can be made (eg, pulmonary, cardiac, and neurologic evaluations as well as rehabilitation medicine specialists). Lastly, it is important for patients and clinicians to keep track and engage with all those caring for the patients and to encourage cross-specialty communication, care coordination, and facilitated access to medical records.

SUMMARY

Cancer survivors may experience a myriad of acute toxicities as well as late and long-term effects as a result of cancer itself, its treatment, and/or concomitant comorbid medical conditions. These effects may have major
consequences for their functioning and ability to work and result in a loss of productivity, increased financial toxicity, and poorer quality of life. Pharmacological and non-pharmacological interventions can be effective for some of the impairments commonly experienced by cancer survivors. When treatments are not effective at alleviating functional limitations and gainful employment is not possible, the US SSA provides a process for cancer survivors to file for disability. However, many barriers prevent long-term survivors from securing approval of their disability claims. Clinicians play a pivotal role in supporting cancer survivors by assessing for and documenting functional limitations in the medical record. This ongoing assessment should also include referring cancer survivors to specialists who can address and manage the complicated symptoms, side effects, impairments, and functional limitations often faced by cancer survivors. Such assessments and documentation will facilitate the disability application if it is needed. Survivors should be educated about the availability of community-based resources, including vocational retraining and, if needed, SSA disability. The use of standardized tools to assess disability by the SSA that take into account the multisystem impairments common among cancer survivors may promote successful applications by those in need. Clinicians are also poised to be at the forefront in educating and promoting policy that supports the enhancement of disability criteria to support the overall well-being of survivors and their families.

**FUNDING SUPPORT**
No specific funding was disclosed.

**CONFLICT OF INTEREST DISCLOSURES**
Grace B. Campbell belongs to the board of directors for the Association of Rehabilitation Nurses. Patricia A. Ganz reports grants from the National Institutes of Health and the Breast Cancer Research Foundation and royalties from UpToDate. Diane Von Ah reports an honorarium from the National Cancer Institute. The other authors made no disclosures.

**REFERENCES**
1. American Cancer Statistics. Cancer Facts & Figures 2021. American Cancer Society; 2021.
2. American Cancer Society. Cancer Treatment & Survivorship Facts & Figures 2019-2021. American Cancer Society; 2019.
3. Von Ah D, Storey S, Crouch A. Relationship between self-reported cognitive function and work-related outcomes in breast cancer survivors. J Cancer Surviv. 2018;12:246-255.
4. Wolvers MDJ, Leenens MCJ, Groeneveld IF, Fringo-Dreesen MHW, De Boer A. Longitudinal associations between fatigue and perceived work ability in cancer survivors. J Occup Rehabil. 2019;29:540-549.
5. de Moor JS, Kent EE, McNeil TS, et al. Employment outcomes among cancer survivors in the United States: implications for cancer care delivery. J Natl Cancer Inst. 2021;113:641-644.
6. Tracy JK, Falk D, Thompson RJ, Scheindlin L, Adetunji F, Swanson JE. Managing the cancer-work interface: the effect of cancer survivorship on unemployment. Cancer Manag Res. 2018;10:6479-6487.
7. Zheng Z, Yabroff KR, Guy GP Jr, et al. Annual medical expenditure and productivity loss among colorectal, female breast, and prostate cancer survivors in the United States. J Natl Cancer Inst. 2016;108:dyw382.
8. National Academies of Sciences, Engineering, and Medicine. Diagnosing and Treating Adult Cancers and Associated Impairments. National Academies Press; 2021.
9. de Boer AG. The European Cancer and Work Network: CANWON. J Occup Rehabil. 2014;24:393-398.
10. Duijts SFA, van Elgrood MP, Gits M, van der Beek AJ, Bleeker EM. Cancer survivors' perspectives and experiences regarding behavioral determinants of return to work and continuation of work. Disabil Rehabil. 2017;39:2164-2172.
11. Peteet JR. Cancer and the meaning of work. Gen Hosp Psychiatry. 2000;22:200-205.
12. Feuerstein M, Todd BL, Moskwitiz MC, et al. Work in cancer survivors: a model for practice and research. J Cancer Surviv. 2010;4:415-437.
13. Islam T, Dalhui M, Majid HA, et al. Factors associated with return to work of breast cancer survivors: a systematic review. BMC Public Health. 2014;14(suppl 3):S8.
14. Mehnert A, de Boer A, Feuerstein M. Employment challenges for cancer survivors. Cancer. 2013;119(suppl 11):2151-2159.
15. Altice CK, Bangsas MP, Tucker-Seeley RD, Yabroff KR. Financial hardships experienced by cancer survivors: a systematic review. J Natl Cancer Inst. 2017;109:dyw205.
16. Yabroff KR, Bradley C, Shih YT. Understanding financial hardship among cancer survivors in the United States: strategies for prevention and mitigation. J Clin Oncol. 2020;38:292-301.
17. Gilligan AM, Alberts DS, Roe DJ, Srepnek GH. Death or debt? National estimates of financial toxicity in persons with newly-diagnosed cancer. Ann J Med. 2018;131:1187-1199.e5.
18. Institute of Medicine. Disability in America: Toward a National Agenda for Prevention. National Academies Press; 1991.
19. Bennedsen K, Ventzel L, Andersen NT, et al. Oxaliplatin- and docetaxel-induced polyneuropathy: clinical and neurophysiological characteristics. J Peripher Nerv Syst. 2020;25:377-387.
20. Swarn RA, Paice JA, Angelescu DL, et al. Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17:977-1007. doi:10.6004/jnccn.2019.0038
21. Berger AM, Mooney K, Alvarez-Perez A, et al; National Comprehensive Cancer Network. Cancer-Related Fatigue, Version 2.2015. J Natl Compr Canc Netw. 2015;13:1012-1039. doi:10.6004/jnccn.2015.0122
22. McGrady JM, Goldstein D, Trinh T, et al. Optimizing clinical screening for chemotherapy-induced peripheral neuropathy. J Pain Symptom Manage. 2019;58:1023-1032.
23. Rolke R, Magef M, Campbell KA, et al. Quantitative sensory testing: a comprehensive protocol for clinical trials. Eur J Pain. 2006;10:77-88.
24. Hidding JT, Viehoff PB, Beurskens CH, van Laarhoven HW, Nijhuis-van der Sanden MW, van der Wees PJ. Measurement properties of instruments for measuring of lymphedema: systematic review. Phys Ther. 2016;96:1965-1981. doi:10.2529/ptj.20150412
25. Fearn K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489-495.
26. Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2011;35:893-911.
27. Jain D, Russell RR, Schwartz RG, Panjrath GS, Aronow W. Cardiac complications of cancer therapy: pathophysiology, identification, prevention, treatment, and future directions. Curr Cardiol Rep. 2017;19:36.
28. Isenberg-Greeda E, Huband H, Lam A. A review of cognitive screening tools in cancer. Curr Opin Support Palliat Care. 2017;11:24-31.
29. Cheung YT, Tan EH, Chan A. An evaluation on the neuropsychological tests used in the assessment of postchemotherapy cognitive changes in breast cancer survivors. Support Care Cancer. 2012;20:1361-1375.
30. Andersen BL, DeRubeis RJ, Berman BS, et al. Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an
Functional Impairments After Cancer/Nekhlyudov et al

American Society of Clinical Oncology guideline adaptation. J Clin Oncol. 2014;32:1605-1619.

31. Gastrointestinal Complications (PDQ®)—Health Professional Version. National Cancer Institute. Accessed August 3, 2021. https://www.cancer.gov/about-cancer/treatment/side-effects/constipation/gi-complications-hp-pdq

32. Teh C, Onstad L, Lee SJ. Reliability and validity of the modified 7-day Lee Chronic Graft-Versus-Host Disease Symptom Scale. Biol Blood Marrow Transplant. 2020;26:562-567.

33. Gralow JR, Biermann JS, Farooki A, et al. NCCN task force report: bone health in cancer care. J Natl Compr Canc Netw. 2013;11(suppl 3):S1-S50.

34. Beckwee D, Leysen L, Metwies K, Adriaenssens N. Prevalence of aromatase inhibitor–induced arthralgia in breast cancer: a systematic review and meta-analysis. Support Care Cancer. 2017;25:1673-1686.

35. Watts NB, Bilezkian JP, Camacho PM, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. Endocr Pract. 2010;16:1016-1019.

36. Shannon VR. Cancer treatment–related lung injury. In: Nates JL, Price KJ, eds. Oncologic Critical Care. Springer Nature; 2020:531-556.

37. Li F, Zhou Z, Wu A, et al. Preexisting radiological interstitial lung abnormalities are a risk factor for severe radiation pneumonitis in patients with small-cell lung cancer after thoracic radiation therapy. Radiat Oncol. 2018;13:82.

38. Buysse DJ, Yu L, Moul DE, et al. Development and validation of patient-reported outcome measures for sleep disturbance and sleep-related impairments. Sleep. 2010;33:781-792.

39. American Academy of Sleep Medicine. International Classification of Sleep Disorders. American Academy of Sleep Medicine; 2014.

40. Fan G, Filipczak L, Chow E. Symptom clusters in cancer patients: a review of the literature. Curr Oncol. 2007;14:173-179.

41. Dong ST, Costa DS, Butow PN, et al. Symptom clusters in advanced cancer patients: an empirical comparison of statistical methods and the impact on quality of life. J Pain Symptom Manage. 2016;51:88-98.

42. Chiu CY, Chan F, Strauser D, et al. State rehabilitation services tailored to employment status among cancer survivors. J Occup Rehabil. 2014;24:89-99.

43. McCabe MS, Bhatia S, Oeffinger KC, et al. American Society of Clinical Oncology statement: achieving high-quality cancer survivorship care. J Clin Oncol. 2013;31:631-640.

44. Marfeo EE, Haley SM, Jette AM, et al. Conceptual foundation for measures of physical function and behavioral health function for Social Security work disability evaluation. Arch Phys Med Rehabil. 2013;94:1645-1652.e2.

45. Ni P, McDonough CM, Jette AM, et al. Development of a computer-adaptive physical function instrument for Social Security Administration disability determination. Arch Phys Med Rehabil. 2013;94:1661-1669.